Springhill Fund Asset Management HK Co Ltd Makes New $3.02 Million Investment in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Springhill Fund Asset Management HK Co Ltd purchased a new stake in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 160,500 shares of the company’s stock, valued at approximately $3,024,000. Nurix Therapeutics makes up approximately 4.9% of Springhill Fund Asset Management HK Co Ltd’s portfolio, making the stock its 12th biggest position. Springhill Fund Asset Management HK Co Ltd owned about 0.21% of Nurix Therapeutics as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Corebridge Financial Inc. increased its stake in Nurix Therapeutics by 2.3% during the 4th quarter. Corebridge Financial Inc. now owns 34,907 shares of the company’s stock valued at $658,000 after purchasing an additional 770 shares in the last quarter. US Bancorp DE increased its position in shares of Nurix Therapeutics by 144.7% during the fourth quarter. US Bancorp DE now owns 1,424 shares of the company’s stock valued at $27,000 after acquiring an additional 842 shares in the last quarter. Teachers Retirement System of The State of Kentucky raised its holdings in Nurix Therapeutics by 8.4% in the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 30,024 shares of the company’s stock worth $675,000 after acquiring an additional 2,329 shares during the last quarter. Quarry LP lifted its position in Nurix Therapeutics by 3,746.2% in the 3rd quarter. Quarry LP now owns 2,500 shares of the company’s stock valued at $56,000 after acquiring an additional 2,435 shares in the last quarter. Finally, Teacher Retirement System of Texas boosted its stake in Nurix Therapeutics by 18.4% during the 4th quarter. Teacher Retirement System of Texas now owns 16,263 shares of the company’s stock valued at $306,000 after purchasing an additional 2,532 shares during the last quarter.

Insider Activity at Nurix Therapeutics

In related news, CFO Houte Hans Van sold 2,811 shares of the company’s stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $19.85, for a total transaction of $55,798.35. Following the completion of the transaction, the chief financial officer now owns 39,549 shares in the company, valued at approximately $785,047.65. This represents a 6.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Gwenn Hansen sold 3,690 shares of Nurix Therapeutics stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $19.85, for a total transaction of $73,246.50. Following the completion of the sale, the insider now owns 55,937 shares in the company, valued at approximately $1,110,349.45. This represents a 6.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 12,326 shares of company stock valued at $213,449. 7.20% of the stock is owned by company insiders.

Nurix Therapeutics Price Performance

Shares of NASDAQ:NRIX opened at $9.69 on Friday. The company has a market capitalization of $738.73 million, a P/E ratio of -3.35 and a beta of 2.23. Nurix Therapeutics, Inc. has a 1-year low of $9.45 and a 1-year high of $29.56. The firm’s 50 day simple moving average is $15.45 and its two-hundred day simple moving average is $19.89.

Nurix Therapeutics (NASDAQ:NRIX) last issued its earnings results on Tuesday, January 28th. The company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.08). Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%. On average, sell-side analysts anticipate that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. Royal Bank of Canada boosted their price target on Nurix Therapeutics from $26.00 to $27.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 29th. JPMorgan Chase & Co. lowered their target price on shares of Nurix Therapeutics from $31.00 to $30.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 29th. Leerink Partners began coverage on shares of Nurix Therapeutics in a research note on Monday, March 17th. They issued a “market perform” rating and a $16.00 price target for the company. BTIG Research initiated coverage on shares of Nurix Therapeutics in a research report on Tuesday, December 10th. They set a “buy” rating and a $35.00 price objective on the stock. Finally, Stifel Nicolaus lifted their target price on shares of Nurix Therapeutics from $34.00 to $36.00 and gave the stock a “buy” rating in a research report on Wednesday, January 29th. Three research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $30.88.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.